Avience Biomedicals SME IPO Details 2026
All About Avience Biomedicals IPO:
The Avience Biomedicals Limited size is ₹30.24 crore, including a fresh issue of ₹30.24 crore and an offer for sale of – crore. It is a book build issue. The IPO issue opens on June 18, 2026 and closes on June 22, 2026. The share allotment is expected on June 23, 2026, and the listing date is June 25, 2026. Avience Biomedicals Limited is based in Delhi and operates in the Pharmaceutical sector. It filed its DRHP on 23rd July 2025 and will list its shares on NSE SME. Skyline Financial Services Pvt.Ltd. is the registrar, while Fintellectual Corporate Advisors Pvt.Ltd. serves as the merchant banker for the offer.
IPO Highlights
IPO Reservation and Lot Size
The company has reserved shares for various investor categories. The Retail Shares reservation is 35.08% (4,81,200 shares), and QIB has 49.83% (6,83,400 shares). Further, the minimum lot size is 600 shares. The anchor investor reservation is 28.19% (4,09,800 shares), and the market maker reservation is 5.65% (82,200 shares).
IPO Issue Structure
QIB | 6,83,400 (49.83%) |
| Anchor Investor | 4,09,800 (28.19%) |
| QIB (Ex. Anchor) | 2,73,600 (18.82%) |
NII (HNI) | 2,07,000 (15.09%) |
| bNII > ₹10L | 1,38,000 (9.49%) |
| sNII < ₹10L | 69,000 (4.75%) |
Retail | 4,81,200 (35.08%) |
Market Maker | 82,200 (approx. ₹1.71 Cr) |
Total | 14,53,800 (100%) |
On 23rd July 2025 the company filed its Draft Red Herring Prospectus. The Red Herring Prospectus is available to understand the business operations, financials, and the risks involved.
IPO GMP
The Grey Market Premium indicates the extra price that people pay in the unofficial market. This value changes daily based on demand for the shares. Track live GMP Today here.
Financial Performance (₹ in Cr)
| Period Ended | 31 Jan 2026 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Total Income | 41.94 | 45.97 | 24.37 | – |
| Profit After Tax | 5.74 | 7.23 | 2.14 | – |
| EBITDA | 10.34 | 11.41 | 4.08 | – |
| Net Worth | 28.52 | 22.78 | 6.21 | – |
| Assets | 66.07 | 56.52 | 34.65 | – |
| Total Debt | 26.73 | 22.16 | 15 | – |
Key Performance Indicator
| Particulars | 2025/2026 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| EBITDA Margin (%) | 16.97 | 26.8 | 18.57 | 12.82 |
| PAT Margin (%) | 9.99 | 16.12 | 9.02 | 7.14 |
| EPS (₹) | 14.24 | 19.22 | 6.59 | 2.94 |
| ROE (%) | 16.92 | 31.9 | 34.62 | 19.16 |
| ROCE (%) | 16.99 | 24.84 | 18.09 | 29.2 |
| ROA (%) | 8.04 | 12.9 | 6 | 7.78 |
| Debt to Equity (x) | 0.7 | 0.97 | 2 | 0.65 |
To understand the above financial ratios / financial performance metrics as per the Draft Red Herring Prospectus.
Avience Biomedicals SME IPO Review
You must look at the financial position of the company before deciding on the investments. You can read our full review article here.
Disclaimer: The information provided on this website is for general informational purposes only. Before making any investment decisions, you must consult with a qualified financial adviser.
IPO Financial Snapshot
Avience Biomedicals Company Details
Avience Biomedicals Limited started its business in 2024. The company operates in the Pharmaceutical sector. It manufactures molecular diagnostic solutions for the B2B and B2G market. Its main office is in Delhi. The firm employs 108 workers in various departments. The company holds several quality certificates for its operations including ISO certification.
The business setup sits in Noida inside Uttar Pradesh. They make items for Pharmaceutical setups across nationwide zones. They also focus on export targets for international setups. The business handles trading tasks along with direct production work.
Main Offerings:
Key Strength:
Company Address: C-11, Block-C, Community Centre, Janakpuri A-3, Delhi, New Delhi, 110058
You can contact the company via call or email.
1800-12-04-636 / info@avienbio.com
Intermediaries & Key Contacts
Frequently Asked Questions
Avience Biomedicals IPO offers 14,53,800 equity shares priced between ₹196 and ₹208, opening on June 18, 2026, and closing on June 22, 2026. The total issue size stands at ₹30.24 crore. The entire offer contains fresh equity shares without any offer for sale portion.
The company fixed the price band from ₹196 to ₹208 per share. Investors can choose any price within this range.
The retail group needs to bid for at least 2 lots together. This application equals 1,200 shares costing a total of ₹2,49,600.
The platform chosen for this listing is the NSE SME platform. The final trading depends on formal stock exchange approval.
The company appointed Skyline Financial Services Pvt.Ltd. as the official registrar. They handle all applications and final allotments.
The bidding starts on June 18, 2026 for all investor groups. The subscription channel closes on June 22, 2026 evening.
No comments yet. Be the first to share your thoughts!